Comparison of platforms for determining tumour mutational burden (TMB) in patients with non-small cell lung cancer (NSCLC)

Jonathan Baden(Bristol-Myers Squibb (United States)), Traci Pawlowski(Illumina (United States)), Stefan Kirov(Johns Hopkins University), Sven Bilke(Illumina (United States)), G. Green(Bristol-Myers Squibb (United States)), Shubham Pant(The University of Texas MD Anderson Cancer Center), Ina L. Deras(Illumina (United States)), Chen Zhao(Illumina (United States)), David Fabrizio(Foundation Medicine (United States)), James Pratt(Bristol-Myers Squibb (United States)), A. Seminara(Bristol-Myers Squibb (United States))
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz239.001
Cited by 7

Related Papers

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
|Cancer Immunology Research|2016|493
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453